Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2528-2536

  Ishikawa, S ^a,b   Hayashi, H ^a   Kinoshita, K ^a   Abe, M ^c   Kuroki, H ^a   Tokunaga, R ^b   Tomiyasu, S ^b   Tanaka, H ^b   Sugita, H ^b   Arita, T ^b   Yagi, Y ^b   Watanabe, M ^a   Hirota, M ^b   Baba, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Regional Medical Center   (Japan)

^c Minamata City Hospital and Medical Center   (Japan)

Author keywords

colorectal cancer; EZH2; HDAC; p27; Statins

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; ATORVASTATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLUINDOSTATIN; FLUOROURACIL; HISTONE DEACETYLASE 5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PRAVASTATIN; SIMVASTATIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; CDKN1B PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; MESSENGER RNA; POLYCOMB REPRESSIVE COMPLEX 2;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; EPIGENETICS; EZH2 GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOENZYME TECHNIQUES; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84927695260     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28672     Document Type: Article

References (21)

1. International Agency for Research on Cancer, "Globocan 2008 Facts Stats," 2010.
2. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
3. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.
4. Larner J, Jane J, Laws E, et al. A Phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998;21:579-83.
5. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomize controlled trial. Br J Cancer 2001;84:886-91.
6. Lee J, Jung KH, Park YS, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 2009;64:657-63.
7. Katz MS, Minsky BD, Saltz LB, et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:1363-70.
8. Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011;103:1540-51.
9. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
10. Agarwal B, Bhendwal S, Halmos B, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999;5:2223-9.
11. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001;22:1061-7.
12. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzym A reductase inhibitors. Cancer Res 2001;61:4884-91.
13. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
14. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419: 624-9.
15. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11.
16. Fluge Ø, Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009;101:1282-9.
17. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation Res 2008;647:21-9.
18. Sato R, Inoue J, Kawabe Y, et al. Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2. J Biol Chem 1996;271: 26461-64.
19. Scanlan MJ, Welt S, Gordon CM, et al. Cancerrelated serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62: 4041-47.
20. Huang Y, Tan M, Gosink M, et al. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res 2002;62: 2913-22.
21. Naldi M, Calonghi N, Masotti L, et al. Histone post-translational modifications by HPLC-ESIMS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics 2009;9:5437-45.